InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Greenleaf Peter, Director. Director active across 4 companies, notably Pelthos Therapeutics Inc.. Cumulatively, 13 filings have been published. Total volume traded: €36k. The latest transaction was disclosed on 2 July 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations13 total
025,478 shares0
Common Stock
SEC:0001919246-26-000043·
025,478 shares0
Common Stock
SEC:0001919246-26-000043:0·
€157,62330,220 shares@ €5.215846.0% of flow
Common Stock
SEC:0000899243-22-019780:0·
0105,034 shares0
Common Stock
SEC:0001103021-22-000067:0·
028,300 shares0
Common Stock
SEC:0001628280-22-005123:0·
010,246 shares0
Common Stock
SEC:0001103021-22-000021:0·
010,246 shares0
Common Stock
SEC:0001103021-22-000021·
035,000 shares0
Common Stock
SEC:0001103021-21-000070·
035,000 shares0
Common Stock
SEC:0001103021-21-000070:0·
€92,41925,452 shares@ €3.6311100.0% of flow
Common Stock
SEC:0001209191-21-040329·
€92,41925,452 shares@ €3.631127.0% of flow
Common Stock
SEC:0001209191-21-040329:0·
€17,8272,133 shares@ €8.3577100.0% of flow
Common Stock
SEC:0001628280-21-010022·
Ideal exit: 5 Feb 2022 (T+270)
€17,8272,133 shares@ €8.35770.0008% mcap50.0% of flow
Common Stock
SEC:0001628280-21-010022:0·
Ideal exit: 5 Feb 2022 (T+270)
13 of 13 declarations
About Greenleaf Peter
Peter Greenleaf is a Director and Chief Executive Officer of Pelthos Therapeutics Inc., Aurinia Pharmaceuticals Inc., and ANTARES PHARMA, INC. He leads these companies with a focus on innovation and the development of new treatments.
